BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv264-iv266. [PMID: 29917046 DOI: 10.1093/annonc/mdy162] [Cited by in Crossref: 173] [Cited by in F6Publishing: 132] [Article Influence: 57.7] [Reference Citation Analysis]
Number Citing Articles
1 Dingemans AM, Hendriks L. Immune checkpoint inhibitors in non-small-cell lung cancer: key to long-term survival? Lancet Respir Med 2019;7:291-2. [PMID: 30876832 DOI: 10.1016/S2213-2600(19)30043-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Mai K, Fassnacht M, Führer-Sakel D, Honegger JB, Weber MM, Kroiss M. The Diagnosis and Management of Endocrine Side Effects of Immune Checkpoint Inhibitors. Dtsch Arztebl Int 2021;118:arztebl. [PMID: 33724917 DOI: 10.3238/arztebl.m2021.0143] [Reference Citation Analysis]
3 Voon PJ, Cella D, Hansen AR. Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies. Cancer 2021;127:1360-8. [PMID: 33662145 DOI: 10.1002/cncr.33457] [Reference Citation Analysis]
4 Czarnecka AM, Rutkowski P. An update on the safety of nivolumab for the treatment of advanced melanoma. Expert Opin Drug Saf 2020;19:409-21. [PMID: 32293935 DOI: 10.1080/14740338.2020.1757068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Cohen JV, Dougan M, Zubiri L, Reynolds KL, Sullivan RJ, Misdraji J. Liver biopsy findings in patients on immune checkpoint inhibitors. Mod Pathol 2021;34:426-37. [PMID: 32884128 DOI: 10.1038/s41379-020-00653-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
6 Virizuela JA, García AM, de Las Peñas R, Santaballa A, Andrés R, Beato C, de la Cruz S, Gavilá J, González-Santiago S, Fernández TL. SEOM clinical guidelines on cardiovascular toxicity (2018). Clin Transl Oncol 2019;21:94-105. [PMID: 30627982 DOI: 10.1007/s12094-018-02017-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
7 Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Russano M, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes. Clin Lung Cancer 2020;21:498-508.e2. [PMID: 32680806 DOI: 10.1016/j.cllc.2020.06.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
8 Sise ME, Seethapathy H, Reynolds KL. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. Oncologist 2019;24:735-42. [PMID: 30902916 DOI: 10.1634/theoncologist.2018-0764] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 9.5] [Reference Citation Analysis]
9 Gao L, Yang X, Yi C, Zhu H. Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review. Front Pharmacol 2019;10:1173. [PMID: 31680957 DOI: 10.3389/fphar.2019.01173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
10 Beck TN, Kudinov AE, Dulaimi E, Boumber Y. Case report: reinitiating pembrolizumab treatment after small bowel perforation. BMC Cancer 2019;19:379. [PMID: 31018834 DOI: 10.1186/s12885-019-5577-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
11 Ciccarese F, Piccinino A, Brocchi S, Balacchi C, Dall'Olio FG, Massari F, Rihawi K, Paccapelo A, Ardizzoni A, Golfieri R. Expected and non-expected immune-related adverse events detectable by CT. Eur J Radiol 2021;138:109617. [PMID: 33676358 DOI: 10.1016/j.ejrad.2021.109617] [Reference Citation Analysis]
12 Giannini EG, Aglitti A, Borzio M, Gambato M, Guarino M, Iavarone M, Lai Q, Levi Sandri GB, Melandro F, Morisco F, Ponziani FR, Rendina M, Russo FP, Sacco R, Viganò M, Vitale A, Trevisani F; Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers (Basel) 2019;11:E1689. [PMID: 31671581 DOI: 10.3390/cancers11111689] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
13 Gou M, Zhang Y, Liu T, Si H, Wang Z, Yan H, Qian N, Dai G. PD-1 Inhibitors Could Improve the Efficacy of Chemotherapy as First-Line Treatment in Biliary Tract Cancers: A Propensity Score Matching Based Analysis. Front Oncol 2021;11:648068. [PMID: 34221968 DOI: 10.3389/fonc.2021.648068] [Reference Citation Analysis]
14 Kooshkaki O, Derakhshani A, Hosseinkhani N, Torabi M, Safaei S, Brunetti O, Racanelli V, Silvestris N, Baradaran B. Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. Int J Mol Sci 2020;21:E4427. [PMID: 32580338 DOI: 10.3390/ijms21124427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
15 Kostine M, Cappelli LC, Calabrese C, Calabrese LH, Bingham CO 3rd, Richez C, Gottenberg JE, Lambotte O. Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists? Ann Rheum Dis 2019;78:860-2. [PMID: 30659050 DOI: 10.1136/annrheumdis-2018-214748] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
16 Mekki A, Dercle L, Lichtenstein P, Nasser G, Marabelle A, Champiat S, Chouzenoux E, Balleyguier C, Ammari S. Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy. Eur J Cancer 2019;119:44-56. [PMID: 31415986 DOI: 10.1016/j.ejca.2019.06.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
17 Parikh M, Powles T. Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management. Am Soc Clin Oncol Educ Book 2021;41:e182-9. [PMID: 34061558 DOI: 10.1200/EDBK_323835] [Reference Citation Analysis]
18 Harries I, Liang K, Williams M, Berlot B, Biglino G, Lancellotti P, Plana JC, Bucciarelli-Ducci C. Magnetic Resonance Imaging to Detect Cardiovascular Effects of Cancer Therapy: JACC CardioOncology State-of-the-Art Review. JACC CardioOncol 2020;2:270-92. [PMID: 34396235 DOI: 10.1016/j.jaccao.2020.04.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
19 Zarkavelis G, Mauri D, Karassa F, Eleftherios K, Pentheroudakis G, Pappadaki A, Mavroeidis L, Ntellas P, Gkoura S, Gazouli I. The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature. Contemp Oncol (Pozn) 2020;24:75-8. [PMID: 32514241 DOI: 10.5114/wo.2020.94727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ziogas DC, Kostantinou F, Cholongitas E, Anastasopoulou A, Diamantopoulos P, Haanen J, Gogas H. Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. J Immunother Cancer 2020;8:e000943. [PMID: 33067316 DOI: 10.1136/jitc-2020-000943] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
21 Kitamura N, Sento S, Yoshizawa Y, Sasabe E, Kudo Y, Yamamoto T. Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. Int J Mol Sci 2020;22:E240. [PMID: 33383632 DOI: 10.3390/ijms22010240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Wang YN, Lou DF, Li DY, Jiang W, Dong JY, Gao W, Chen HC. Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Oncol Lett 2020;20:611-22. [PMID: 32565986 DOI: 10.3892/ol.2020.11618] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
23 Frayberg M, Yung A, Zubiri L, Zlotoff DA, Reynolds KL. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. Curr Treat Options Oncol 2021;22:53. [PMID: 34037918 DOI: 10.1007/s11864-021-00844-1] [Reference Citation Analysis]
24 Russano M, Citarella F, Napolitano A, Dell'Aquila E, Cortellini A, Pantano F, Vincenzi B, Tonini G, Santini D. COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management. Expert Opin Biol Ther. 2020;20:959-964. [PMID: 32588674 DOI: 10.1080/14712598.2020.1789097] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
25 McClure T, Cui W, Asadi K, John T, Testro A. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up. BMJ Open Gastroenterol 2020;7:e000487. [PMID: 32912846 DOI: 10.1136/bmjgast-2020-000487] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Choi J, Lee SY. Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. Immune Netw. 2020;20:e9. [PMID: 32158597 DOI: 10.4110/in.2020.20.e9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 31.0] [Reference Citation Analysis]
27 Hirano H, Kato K. Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Jpn J Clin Oncol. 2019;49:412-420. [PMID: 30920626 DOI: 10.1093/jjco/hyz034] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
28 Bobrowicz M, Zagozdzon R, Domagala J, Vasconcelos-Berg R, Guenova E, Winiarska M. Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives. Cancers (Basel) 2019;11:E1420. [PMID: 31554169 DOI: 10.3390/cancers11101420] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
29 Grimm M, Bex A, De Santis M, Ljungberg B, Catto JW, Rouprêt M, Hussain SA, Bellmunt J, Powles T, Wirth M, Van Poppel H. Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. European Urology 2019;76:368-80. [DOI: 10.1016/j.eururo.2019.05.041] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
30 Upadhrasta S, Elias H, Patel K, Zheng L. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med 2019;5:6-14. [PMID: 30993259 DOI: 10.1016/j.cdtm.2019.02.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
31 Solinas C, Gu-Trantien C, Willard-Gallo K. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open 2020;5:e000544. [PMID: 32516116 DOI: 10.1136/esmoopen-2019-000544] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 20.0] [Reference Citation Analysis]
32 Shah M, Rajha E, Dinardo C, Muckey E, Wierda WG, Yeung SJ. Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. Annals of Emergency Medicine 2020;75:264-86. [DOI: 10.1016/j.annemergmed.2019.07.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
33 Schulz GB, Rodler S, Szabados B, Graser A, Buchner A, Stief C, Casuscelli J. Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers. J Geriatr Oncol 2020;11:1061-6. [PMID: 32565147 DOI: 10.1016/j.jgo.2020.06.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Lacouture ME, Sibaud V, Gerber PA, van den Hurk C, Fernández-Peñas P, Santini D, Jahn F, Jordan K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol 2021;32:157-70. [PMID: 33248228 DOI: 10.1016/j.annonc.2020.11.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
35 Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH Jr. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 2020;27:S87-97. [PMID: 32368178 DOI: 10.3747/co.27.5223] [Cited by in Crossref: 86] [Cited by in F6Publishing: 61] [Article Influence: 86.0] [Reference Citation Analysis]
36 Vindum HH, Agnholt JS, Nielsen AWM, Nielsen MB, Schmidt H. Severe steroid refractory gastritis induced by Nivolumab: A case report. World J Gastroenterol 2020;26:1971-8. [PMID: 32390707 DOI: 10.3748/wjg.v26.i16.1971] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
37 Esfahani K, Meti N, Miller WH, Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ. 2019;191:E40-E46. [PMID: 30642824 DOI: 10.1503/cmaj.180870] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
38 Kotecki N, Vuagnat P, O'Neil BH, Jalal S, Rottey S, Prenen H, Benhadji KA, Xia M, Szpurka AM, Saha A, Wallin J, Suriyapperuma S, Galvao VR, Geeganage S, Doman TN, Gandhi L, Xu X, Bendell J. A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer. J Immunother 2021;44:264-75. [PMID: 33928928 DOI: 10.1097/CJI.0000000000000368] [Reference Citation Analysis]
39 Abou Alaiwi S, Xie W, Nassar AH, Dudani S, Martini D, Bakouny Z, Steinharter JA, Nuzzo PV, Flippot R, Martinez-Chanza N, Wei X, McGregor BA, Kaymakcalan MD, Heng DYC, Bilen MA, Choueiri TK, Harshman LC. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. J Immunother Cancer. 2020;8. [PMID: 32066646 DOI: 10.1136/jitc-2019-000144] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
40 Yasumatsu R, Matsuo M, Wakasaki T, Masuda M, Takeuchi T, Manako T, Jiromaru R, Uchi R, Hashimoto K, Nakagawa T. Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events. Acta Oto-Laryngologica 2020;140:1043-8. [DOI: 10.1080/00016489.2020.1807601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Lee SL, Al-Shamkhani A, Mirnezami A. Immuno-oncology for surgeons. Br J Surg 2019;106:1273-82. [PMID: 31318438 DOI: 10.1002/bjs.11224] [Reference Citation Analysis]
42 Benesova K, Lorenz HM, Leipe J, Jordan K. How I treat cancer: treatment of rheumatological side effects of immunotherapy. ESMO Open 2019;4:e000529. [PMID: 31423343 DOI: 10.1136/esmoopen-2019-000529] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
43 Marco T, Anna P, Annalisa T, Francesco M, Stefania SL, Stella D, Michele R, Marco T, Loreto G, Franco S. The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. Ther Adv Med Oncol 2019;11:1758835919875549. [PMID: 31579108 DOI: 10.1177/1758835919875549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
44 Ferrara R, Campochiaro C, Garassino MC. Shifting From a “One Size Fits All” to a Tailored Approach for Immune-Related Adverse Events. Journal of Thoracic Oncology 2021;16:183-6. [DOI: 10.1016/j.jtho.2020.11.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Wang D, Wei X, Kalvakolanu DV, Guo B, Zhang L. Perspectives on Oncolytic Salmonella in Cancer Immunotherapy-A Promising Strategy. Front Immunol 2021;12:615930. [PMID: 33717106 DOI: 10.3389/fimmu.2021.615930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Zhai X, Zhang J, Tian Y, Li J, Jing W, Guo H, Zhu H. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. Cancer Biol Med 2020;17:599-611. [PMID: 32944393 DOI: 10.20892/j.issn.2095-3941.2020.0102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
47 Naidoo J, Reuss JE, Suresh K, Feller-Kopman D, Forde PM, Mehta Steinke S, Rock C, Johnson DB, Nishino M, Brahmer JR. Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management.J Immunother Cancer. 2020;8. [PMID: 32554619 DOI: 10.1136/jitc-2020-000984] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
48 Lin X, Deng H, Chen L, Wu D, Chen X, Yang Y, Chen T, Xie X, Xie Z, Liu M, Ouyang M, Qin Y, Li S, Zhong N, Gregg JP, Horita N, Song Y, Zhou C. Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience. Transl Lung Cancer Res 2021;10:415-29. [PMID: 33569323 DOI: 10.21037/tlcr-20-1258] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Ruggiero R, Fraenza F, Scavone C, di Mauro G, Piscitelli R, Mascolo A, Ferrajolo C, Rafaniello C, Sportiello L, Rossi F, Capuano A. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. Front Pharmacol 2020;11:830. [PMID: 32581796 DOI: 10.3389/fphar.2020.00830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Hayashi Y, Hosoe N, Takabayashi K, Limpias Kamiya KJL, Tsugaru K, Shimozaki K, Hirata K, Fukuhara K, Fukuhara S, Mutaguchi M, Sujino T, Sukawa Y, Hamamoto Y, Naganuma M, Takaishi H, Shimoda M, Ogata H, Kanai T. Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis. Dig Dis Sci. 2021;66:2129-2134. [PMID: 32621258 DOI: 10.1007/s10620-020-06441-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
51 Fessas P, Possamai LA, Clark J, Daniels E, Gudd C, Mullish BH, Alexander JL, Pinato DJ. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology 2020;159:167-77. [PMID: 31646612 DOI: 10.1111/imm.13141] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 15.5] [Reference Citation Analysis]
52 De Silva P, Aiello M, Gu-Trantien C, Migliori E, Willard-Gallo K, Solinas C. Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations? Int J Cancer 2021;149:31-41. [PMID: 33252786 DOI: 10.1002/ijc.33415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
53 McKelvey KJ, Hudson AL, Prasanna Kumar R, Eade T, Clarke SJ, Wheeler HR, Diakos CI, Howell VM. Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer. Front Oncol 2019;9:1504. [PMID: 32010614 DOI: 10.3389/fonc.2019.01504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M. Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer 2019;7:226. [PMID: 31439050 DOI: 10.1186/s40425-019-0711-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 18.5] [Reference Citation Analysis]
55 Grivas P, Agarwal N, Pal S, Kalebasty AR, Sridhar SS, Smith J, Devgan G, Sternberg CN, Bellmunt J. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Cancer Treat Rev 2021;97:102187. [PMID: 33839438 DOI: 10.1016/j.ctrv.2021.102187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Wu CE, Yang CK, Peng MT, Huang PW, Chang CF, Yeh KY, Chen CB, Wang CL, Hsu CW, Chen IW, Lin CT, Ueng SH, Lin G, Lin YF, Cheng CY, Chang JW. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies. BMC Cancer 2020;20:1018. [PMID: 33087090 DOI: 10.1186/s12885-020-07508-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Kostine M, Marabelle A, Schaeverbeke T, Kfoury M. [Toxicities of immune checkpoint inhibitors and their management]. Med Sci (Paris) 2019;35:949-56. [PMID: 31903899 DOI: 10.1051/medsci/2019191] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Kashiwabara K, Fujii S, Tsumura S, Sakamoto K. Timing of resumption of immune checkpoint inhibitor therapy after successful control of immune-related adverse events in seven advanced non-small cell lung cancer patients. Anticancer Drugs 2020;31:872-5. [PMID: 32796406 DOI: 10.1097/CAD.0000000000000957] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Wu F, Gu Y, Kang B, Heskia F, Pachot A, Bonneville M, Wei P, Liang J. PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer. Transl Lung Cancer Res 2021;10:2441-51. [PMID: 34295653 DOI: 10.21037/tlcr-20-1277] [Reference Citation Analysis]
60 Rapoport BL, Anderson R, Cooksley T, Johnson DB. MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. Support Care Cancer 2020;28:6107-10. [DOI: 10.1007/s00520-020-05727-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
61 Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol 2018;151:374-80. [PMID: 30213435 DOI: 10.1016/j.ygyno.2018.08.037] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Bhatlapenumarthi V, Patwari A, Harb AJ. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience. J Cancer Res Clin Oncol 2021;147:2789-800. [PMID: 33774736 DOI: 10.1007/s00432-021-03610-w] [Reference Citation Analysis]
63 Ito T, Ishigami M, Yamamoto T, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H, Yasuda S, Toyoda H, Yokota K, Hase T, Nishio N, Maeda O, Kato M, Hashimoto N, Hibi H, Kodera Y, Sone M, Ando Y, Akiyama M, Shimoyama Y, Fujishiro M. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. Hepatol Int 2021. [PMID: 34373964 DOI: 10.1007/s12072-021-10238-y] [Reference Citation Analysis]
64 Patel S, Chin V, Greenfield JR. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism. Endocrinol Diabetes Metab Case Rep 2019;2019:EDM190098. [PMID: 31829972 DOI: 10.1530/EDM-19-0098] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
65 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 17.0] [Reference Citation Analysis]
66 Luo W, Zheng L, Zhang T. Do novel treatment strategies enhance T cell-mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapy. Int Immunopharmacol 2021;90:107199. [PMID: 33246828 DOI: 10.1016/j.intimp.2020.107199] [Reference Citation Analysis]
67 Rodler S, Buchner A, Stief CG, Heinemann V, Staehler M, Casuscelli J. Patients' Perspective on Digital Technologies in Advanced Genitourinary Cancers. Clin Genitourin Cancer 2021;19:76-82.e6. [PMID: 32527682 DOI: 10.1016/j.clgc.2020.03.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
68 Brilli L, Danielli R, Campanile M, Secchi C, Ciuoli C, Calabrò L, Pilli T, Cartocci A, Pacini F, Di Giacomo AM, Castagna MG. Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. J Endocrinol Invest 2021;44:1719-26. [PMID: 33367977 DOI: 10.1007/s40618-020-01480-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Weill A, Delyon J, Descamps V, Deschamps L, Dinulescu M, Dupuy A, Célérier P, Nardin C, Aubin F, Le Corre Y, Heidelberger V, Maubec E, Malissen N, Longvert C, Machet L, Gounant V, Brosseau S, Bonniaud B, Jeudy G, Psimaras D, Doucet L, Lebbe C, Zalcman G, De Masson A, Baroudjian B, Leonard-Louis S, Hervier B, Brunet-Possenti F; Groupe de Cancérologie Cutanée and PATIO Group. Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: A national multicenter study. Rheumatology (Oxford) 2021:keab249. [PMID: 33725115 DOI: 10.1093/rheumatology/keab249] [Reference Citation Analysis]
70 Wang F, Qin S, Sun X, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Yan P, Zou J. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol 2020;13:47. [PMID: 32393323 DOI: 10.1186/s13045-020-00886-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
71 Rapoport BL, Cooksley T, Johnson DB, Anderson R, Shannon VR. Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). Expert Rev Clin Pharmacol 2021;14:295-313. [PMID: 33517803 DOI: 10.1080/17512433.2021.1884067] [Reference Citation Analysis]
72 Dromain C, Beigelman C, Pozzessere C, Duran R, Digklia A. Imaging of tumour response to immunotherapy. Eur Radiol Exp 2020;4:2. [PMID: 31900689 DOI: 10.1186/s41747-019-0134-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 27.0] [Reference Citation Analysis]
73 Grünwald V, Voss MH, Rini BI, Powles T, Albiges L, Giles RH, Jonasch E. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. Br J Cancer 2020;123:898-904. [PMID: 32587360 DOI: 10.1038/s41416-020-0949-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
74 Han Y, Wang J, Xu B. Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2021;163:103376. [PMID: 34087346 DOI: 10.1016/j.critrevonc.2021.103376] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Siwicki M, Gort-Freitas NA, Messemaker M, Bill R, Gungabeesoon J, Engblom C, Zilionis R, Garris C, Gerhard GM, Kohl A, Lin Y, Zou AE, Cianciaruso C, Bolli E, Pfirschke C, Lin YJ, Piot C, Mindur JE, Talele N, Kohler RH, Iwamoto Y, Mino-Kenudson M, Pai SI, deVito C, Koessler T, Merkler D, Coukos A, Wicky A, Fraga M, Sempoux C, Jain RK, Dietrich PY, Michielin O, Weissleder R, Klein AM, Pittet MJ. Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. Sci Immunol 2021;6:eabi7083. [PMID: 34215680 DOI: 10.1126/sciimmunol.abi7083] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Ziogas DC, Gkoufa A, Cholongitas E, Diamantopoulos P, Anastasopoulou A, Ascierto PA, Gogas H. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. J Immunother Cancer 2020;8:e001322. [PMID: 33144335 DOI: 10.1136/jitc-2020-001322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
77 Trinh B, Sanchez GO, Herzig P, Läubli H. Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. J Immunother Cancer 2019;7:52. [PMID: 30791949 DOI: 10.1186/s40425-019-0528-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
78 Anastasopoulou A, Ziogas DC, Samarkos M, Kirkwood JM, Gogas H. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer 2019;7:239. [PMID: 31484550 DOI: 10.1186/s40425-019-0717-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 21.0] [Reference Citation Analysis]
79 Shubnikova EV, Bukatina TM, Velts NY, Kaperko DA, Kutekhova GV. Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. Bezopasnost' i risk farmakoterapii 2020;8:9-22. [DOI: 10.30895/2312-7821-2020-8-1-9-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Massari F, Mollica V, Rizzo A, Cosmai L, Rizzo M, Porta C. Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opin Drug Saf 2020;19:1329-38. [PMID: 32799582 DOI: 10.1080/14740338.2020.1811226] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 20.0] [Reference Citation Analysis]
81 Tang H, Zhou J, Bai C. The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease. Front Oncol 2021;11:625872. [PMID: 33692958 DOI: 10.3389/fonc.2021.625872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Xiao Y, Zeng L, Shen Q, Zhou Z, Mao Z, Wang Q, Zhang X, Li Y, Yao W. Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors. J Immunol Res 2020;2020:2640273. [PMID: 32832568 DOI: 10.1155/2020/2640273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Peters S, Reck M, Smit EF, Mok T, Hellmann MD. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. Ann Oncol 2019;30:884-96. [PMID: 30912805 DOI: 10.1093/annonc/mdz109] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 35.0] [Reference Citation Analysis]
84 Hakami OA, Ioana J, Ahmad S, Tun TK, Sreenan S, McDermott JH. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma. Endocrinol Diabetes Metab Case Rep 2019;2019:EDM180153. [PMID: 30836329 DOI: 10.1530/EDM-18-0153] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
85 Pozzessere C, Lazor R, Jumeau R, Peters S, Prior JO, Beigelman-Aubry C. Imaging Features of Pulmonary Immune-related Adverse Events. J Thorac Oncol 2021;16:1449-60. [PMID: 34087477 DOI: 10.1016/j.jtho.2021.05.017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Rodler S, Apfelbeck M, Stief C, Heinemann V, Casuscelli J. Lessons from the coronavirus disease 2019 pandemic: Will virtual patient management reshape uro-oncology in Germany? Eur J Cancer 2020;132:136-40. [PMID: 32361628 DOI: 10.1016/j.ejca.2020.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
87 Connolly C, Bambhania K, Naidoo J. Immune-Related Adverse Events: A Case-Based Approach. Front Oncol 2019;9:530. [PMID: 31293970 DOI: 10.3389/fonc.2019.00530] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
88 Aya F, González-Navarro EA, Martínez C, Carcelero E, Arance A. Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication. Immunotherapy 2021;13:745-52. [PMID: 33906373 DOI: 10.2217/imt-2020-0274] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Yeung SJ, Qdaisat A, Chaftari P, Lipe D, Merlin J, Rajha E, Wechsler A, Sandoval M, Viets J, Al-Breiki A, Shah M, Pandey R, Kamal M, Khattab O, Toale K, Wattana M, Elsayem A, Gaeta S, Brock P, Reyes-Gibby C, Alagappan K. Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. J Am Coll Emerg Physicians Open 2020;1:1637-59. [PMID: 33392573 DOI: 10.1002/emp2.12209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
90 Domblides C, Gross-Goupil M, Ravaud A, Poullenot F, Daste A. Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy. Immunotherapy 2021;13:741-4. [PMID: 33906378 DOI: 10.2217/imt-2020-0282] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Hurkmans DP, Sassen SDT, de Joode K, Putter L, Basak EA, Wijkhuijs AJM, Joerger M, Debets R, Koch BCP, Van der Leest CH, Schreurs MWJ, van der Veldt AAM, Aerts JGJV, Mathijssen RHJ, Koolen SLW. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors. J Immunother Cancer 2021;9:e002344. [PMID: 34088739 DOI: 10.1136/jitc-2021-002344] [Reference Citation Analysis]
92 Duranti S, Pietragalla A, Daniele G, Nero C, Ciccarone F, Scambia G, Lorusso D. Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data. Cancers (Basel) 2021;13:2089. [PMID: 33925884 DOI: 10.3390/cancers13092089] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Zhang X, Zhou Y, Chen C, Fang W, Cai X, Zhang X, Zhao M, Zhang B, Jiang W, Lin Z, Ma Y, Yang Y, Huang Y, Zhao H, Xu R, Hong S, Zhang L. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer 2019;7:322. [PMID: 31753012 DOI: 10.1186/s40425-019-0808-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 27] [Article Influence: 20.5] [Reference Citation Analysis]
94 Leow JJ, Liu Z, Tan TW, Lee YM, Yeo EK, Chong YL. Optimal Management of Upper Tract Urothelial Carcinoma: Current Perspectives. Onco Targets Ther 2020;13:1-15. [PMID: 32021250 DOI: 10.2147/OTT.S225301] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
95 Shahzad O, Thompson N, Clare G, Welsh S, Damato E, Corrie P. Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm. Ther Adv Med Oncol 2021;13:1758835921992989. [PMID: 33633802 DOI: 10.1177/1758835921992989] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Chan SL, Yip TC, Wong VW, Tse YK, Yuen BW, Luk HW, Lui RN, Chan HL, Mok TS, Wong GL. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. Cancer Med 2020;9:7052-61. [PMID: 32780516 DOI: 10.1002/cam4.3378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
97 Grimaud F, Penaranda G, Stavris C, Retornaz F, Brunel V, Cailleres S, Pegliasco H, Le Treut J, Grisoni V, Coquet E, Chiche L, Rognon A. Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach. Ther Clin Risk Manag 2021;17:669-77. [PMID: 34234443 DOI: 10.2147/TCRM.S308194] [Reference Citation Analysis]
98 Bian L, Zhang H, Wang T, Zhang S, Song H, Xu M, Yao S, Jiang Z. JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial. Ann Transl Med 2019;7:435. [PMID: 31700871 DOI: 10.21037/atm.2019.09.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
99 Bruyère CL, Souquet PJ, Dalle S, Corbaux P, Boespflug A, Duruisseaux M, Kiakouama-Maleka L, Reverdy T, Maugeais M, Sahin G, Maillet D, Péron J. Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes. Cancers (Basel) 2021;13:2365. [PMID: 34068892 DOI: 10.3390/cancers13102365] [Reference Citation Analysis]
100 Cho HJ, Kim WR, Kim JH, Kim DH, Kim DJ, Kang H. Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report. Ann Coloproctol 2021;37:S39-43. [PMID: 34167190 DOI: 10.3393/ac.2020.00213.0030] [Reference Citation Analysis]
101 Rovers JFJ, Bovenschen HJ. Dermatological side effects rarely interfere with the continuation of checkpoint inhibitor immunotherapy for cancer. Int J Dermatol 2020;59:1485-90. [PMID: 32895923 DOI: 10.1111/ijd.15163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
102 Vuattoux D, Colomer-Lahiguera S, Fernandez PA, Jequier Gygax M, Choucair ML, Beck-Popovic M, Diezi M, Manificat S, Latifyan S, Ramelet AS, Eicher M, Chabane N, Renella R. Cancer Care of Children, Adolescents and Adults With Autism Spectrum Disorders: Key Information and Strategies for Oncology Teams. Front Oncol 2020;10:595734. [PMID: 33552969 DOI: 10.3389/fonc.2020.595734] [Reference Citation Analysis]
103 Iivanainen S, Alanko T, Peltola K, Konkola T, Ekström J, Virtanen H, Koivunen JP. ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study. J Cancer Res Clin Oncol 2019;145:765-74. [PMID: 30666409 DOI: 10.1007/s00432-018-02835-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
104 Gallo M, Guarnotta V, De Cicco F, Rubino M, Faggiano A, Colao A; NIKE Group. Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. J Cancer Res Clin Oncol 2019;145:429-43. [PMID: 30617553 DOI: 10.1007/s00432-019-02839-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
105 Li M, Sack JS, Rahma OE, Hodi FS, Zucker SD, Grover S. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer 2020;126:5088-97. [PMID: 32888341 DOI: 10.1002/cncr.33165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
106 Wu Z, Liu J, Dai R, Wu S. Current status and future perspectives of immunotherapy in bladder cancer treatment. Sci China Life Sci 2021;64:512-33. [PMID: 32926318 DOI: 10.1007/s11427-020-1768-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
107 Moi L, Bouchaab H, Mederos N, Nguyen-Ngoc T, Perreau M, Fenwick C, Vaucher J, Sempoux C, Peters S, Obeid M. Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis. J Thorac Oncol 2021;16:318-26. [PMID: 32956849 DOI: 10.1016/j.jtho.2020.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
108 Urwyler P, Earnshaw I, Bermudez M, Perucha E, Wu W, Ryan S, Mcdonald L, Karagiannis SN, Taams LS, Powell N, Cope A, Papa S. Mechanisms of checkpoint inhibition-induced adverse events. Clin Exp Immunol 2020;200:141-54. [PMID: 31989585 DOI: 10.1111/cei.13421] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
109 Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin 2020;70:86-104. [PMID: 31944278 DOI: 10.3322/caac.21596] [Cited by in Crossref: 144] [Cited by in F6Publishing: 119] [Article Influence: 144.0] [Reference Citation Analysis]
110 Gao CA, Weber UM, Peixoto AJ, Weiss SA. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma. J Immunother Cancer 2019;7:262. [PMID: 31623673 DOI: 10.1186/s40425-019-0748-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
111 McCallen JD, Naqash AR, Marie MA, Atwell DC, Muzaffar M, Sharma N, Amara S, Liles D, Walker PR, Yang LV. Peripheral blood interleukin 6, interleukin 10, and T lymphocyte levels are associated with checkpoint inhibitor induced pneumonitis: a case report. Acta Oncol 2021;60:813-7. [PMID: 33939588 DOI: 10.1080/0284186X.2021.1917001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I. Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:91. [PMID: 32117745 DOI: 10.3389/fonc.2020.00091] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 29.0] [Reference Citation Analysis]
113 Abu-Sbeih H, Wang Y. Gastrointestinal Tract Adverse Events. Adv Exp Med Biol 2020;1244:247-53. [PMID: 32301019 DOI: 10.1007/978-3-030-41008-7_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Ziogas DC, Gogas H. Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al. J Immunother Cancer 2021;9:e002391. [PMID: 33737346 DOI: 10.1136/jitc-2021-002391] [Reference Citation Analysis]
115 Hu R, Chen M, Xu Y, Wang M, Zheng K, Li X. Renal immune-related adverse events of immune checkpoint inhibitor. Asia Pac J Clin Oncol 2020;16:305-11. [PMID: 32573099 DOI: 10.1111/ajco.13387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
116 Zhu L, Wang Z, Stebbing J, Wang Z, Peng L. Immunotherapy-Related Cystitis: Case Report and Review of the Literature. Onco Targets Ther 2021;14:4321-8. [PMID: 34366676 DOI: 10.2147/OTT.S321965] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc 2019;25:100420. [PMID: 31517036 DOI: 10.1016/j.ijcha.2019.100420] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 9.5] [Reference Citation Analysis]
118 Langan EA, Graetz V, Allerheiligen J, Zillikens D, Rupp J, Terheyden P. Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. Lancet Oncol 2020;21:e55-65. [PMID: 31908308 DOI: 10.1016/S1470-2045(19)30674-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 19.0] [Reference Citation Analysis]
119 Gkrania-Klotsas E, Kumararatne DS. Serious Infectious Complications After Rituximab Therapy in Patients With Autoimmunity: Is This the Final Word? Clin Infect Dis 2021;72:738-42. [PMID: 32067045 DOI: 10.1093/cid/ciaa131] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Assoun S, Lemiale V, Azoulay E. Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. Intensive Care Med 2019;45:988-97. [PMID: 31143997 DOI: 10.1007/s00134-019-05650-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
121 Dimitriou F, Urner-Bloch U, Eggenschwiler C, Mitsakakis N, Mangana J, Dummer R, Urner M. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. Eur J Cancer 2021;144:215-23. [PMID: 33373866 DOI: 10.1016/j.ejca.2020.11.027] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Lee KA, Kim HR, Yoon SY. Rheumatic complications in cancer patients treated with immune checkpoint inhibitors. Korean J Intern Med 2019;34:1197-209. [PMID: 31014065 DOI: 10.3904/kjim.2019.060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
123 Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL. Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist 2020;25:6-14. [PMID: 31694890 DOI: 10.1634/theoncologist.2019-0083] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
124 Ouyang T, Cao Y, Kan X, Chen L, Ren Y, Sun T, Yan L, Xiong B, Liang B, Zheng C. Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. Front Oncol 2021;11:621639. [PMID: 34046338 DOI: 10.3389/fonc.2021.621639] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Habib LA, Wolkow N, Freitag SK, Yoon MK. Advances in Immunotherapy and Periocular Malignancy. Semin Ophthalmol 2019;34:327-33. [PMID: 31177931 DOI: 10.1080/08820538.2019.1620813] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
126 Fazer C, Price KA. Management of Immune-Related Dermatitis and Mucositis Associated With Pembrolizumab in Metastatic Human Papillomavirus-Associated Squamous Cell Carcinoma of the Oropharynx. JCO Oncol Pract 2020;16:20s-4s. [PMID: 32045535 DOI: 10.1200/JOP.19.00648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
127 Angelaki A, Lampropoulou DI, Aravantinos G. Immune-related dermatologic toxicities: to make a long story short. Cutaneous and Ocular Toxicology 2020;39:10-2. [DOI: 10.1080/15569527.2019.1685536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Porcu M, De Silva P, Solinas C, Battaglia A, Schena M, Scartozzi M, Bron D, Suri JS, Willard-Gallo K, Sangiolo D, Saba L. Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. Cancers (Basel) 2019;11:E305. [PMID: 30841554 DOI: 10.3390/cancers11030305] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]
129 van Holstein Y, Kapiteijn E, Bastiaannet E, van den Bos F, Portielje J, de Glas NA. Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer. Drugs Aging 2019;36:927-38. [PMID: 31317421 DOI: 10.1007/s40266-019-00697-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 31.0] [Reference Citation Analysis]
130 Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, Atzenhoffer M, Miremont-Salame G, Perault-Pochat MC, Puyade M; French Network of Regional Pharmacovigilance Centers. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. J Immunother Cancer 2020;8:e001622. [PMID: 33428586 DOI: 10.1136/jitc-2020-001622] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
131 Rapoport BL, Cooksley T, Johnson DB, Anderson R. Supportive care for new cancer therapies. Curr Opin Oncol 2021;33:287-94. [PMID: 33756517 DOI: 10.1097/CCO.0000000000000736] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Zhao Y, Peng W, Abbas M, Shi M, Tang Y, Wang L, Yan H. Anaphylactic shock in a small cell lung cancer patient receiving atezolizumab therapy: a rare but potentially fatal complication. Invest New Drugs 2021. [PMID: 34398354 DOI: 10.1007/s10637-021-01163-w] [Reference Citation Analysis]